Q-omics provides the consensus-scored GSDMD profile across patient tissues and cancer cell-line models. GSDMD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GSDMD is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GSDMD protein abundance shows 20,531 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where GSDMD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSDMD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSDMD survival associations across molecular data types. GSDMD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSDMD RNA expression–survival associations across cancer types. High GSDMD expression shows unfavorable associations in UVM, ACC, LGG and KIRC, but favorable associations in SKCM and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GSDMD RNA expression.
This table summarizes GSDMD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GSDMD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSDMD shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, STAD and BRCA. The KIRC box plot shows higher GSDMD RNA expression in tumor versus normal tissue (log2 FC = +0.806, t-test p < 0.001).
This table shows molecular features associated with GSDMD in patient tissues and cancer cell lines. In patient samples, GSDMD shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSDMD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
